Close Menu

NEW YORK – Biomerica said Thursday that it has inked two separate licensing agreements with Mount Sinai’s Icahn School of Medicine in New York for technologies related to a lab-based serological test for SARS-CoV-2.

The technologies, developed at Mount Sinai, are part of a test that uses the ELISA microplate format and can run on open-system equipment located in most US hospitals and clinical laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.